Make your appointment or second opinion with Dana-Farber today to meet with an onsite specialist.

Adult Patients:877-442-3324

Pediatric Patients:888-733-4662

Make Appointment OnlineInternational Patients

Online second opinions

Can’t get to Boston? Explore our Online Second Opinion service to get expert advice from Dana-Farber oncologists.

Request a second opinion

Contact & Directions

Email Dana-Farber

Main Number617-632-3000

Toll-Free Number866-408-DFCI (3324)

Maps & DirectionsContact InformationSend us a Question or Comment

How to Help

Discover the ways to give and how to get involved to support Dana-Farber.

Learn More
Give now

Safety Study of Oral MGCD265 Administered Without Interruption to Subjects With Advanced Malignancies

Status: Recruiting
Phase: Phase 1
Diagnosis: Solid Tumor/Phase I
NCT ID: NCT00697632 (View complete trial on
DFCI Protocol ID: 08-007


In this study, MGCD265, a new anticancer drug under investigation, is given daily to patients with advanced malignancies to study its safety profile.


Conducting Institutions:
Dana-Farber Cancer Institute, Beth-Israel Deaconess Medical Center

Overall PI:
Daniel Cho, MD, Beth Israel Deaconess Medical Center

Site-responsible Investigators:
Geoffrey Shapiro, MD, PhD, Dana-Farber Cancer Institute

Dana-Farber Cancer Institute: Andrew Wolanski, 617-632-6623,
Beth-Israel Deaconess Medical Center: Cancer Trials Call Center, 617-667-3060

Eligibility Criteria

Inclusion Criteria: - Patients with advanced metastatic or unresectable malignancy that is refractory to standard therapy and/or existing therapies are not likely to achieve clinical benefit. The patient's disease must be histologically confirmed; - Evaluable disease; - Last dose of prior chemotherapy, radiation therapy, or investigational agents occurred at least 4 weeks before the start of therapy on Cycle 1 Day 1; - Recovery from the adverse effects of prior therapy at the time of enrollment to ≤ grade 1 (excluding alopecia); - Age ≥ 18 years; - Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2; - Life expectancy greater than 3 months following study entry; - Adequate renal function; - Adequate hepatic parameters; - Adequate bone marrow function; - A negative serum pregnancy test at screening for women of childbearing potential (WOCBP); - Agreement by WOCBP or men whose sexual partners are WOCBP to use two methods of adequate contraception (e.g., hormonal and barrier method) prior to study entry and for the duration of the study. WOCBP and men whose sexual partners are WOCBP must continue to use two methods of contraception for 28 days and 90 days, respectively, after the last dose of study medication; - Ability to understand and willingness to sign a written informed consent document; - Willingness and ability to comply with study visits and activities to be performed only at the study center; and - For the Expanded MTD Cohort, the subject must have tumors that are accessible to biopsy. Exclusion Criteria: - Subjects with uncontrolled concurrent illness; - Subjects with a history of a cardiovascular illness; - Subjects with QTc > 470 msec (including subjects on medication); - Subjects with left ventricular ejection fraction (LVEF) < 50%; - Subjects with leukemias or myelodysplastic syndrome; - Immunocompromised subjects, including; - Subjects with a history of autologous bone marrow transplant (BMT) within the previous five years, or subjects with organ transplants or allogeneic BMT; - Subjects with lung tumor lesions with increased likelihood of bleeding, including: history of hemoptysis; evidence of cavitation; and invasion of aorta or pulmonary arteries by the tumor; - Subjects with a history of brain metastasis or leptomeningeal disease; subjects with tumors likely to metastasize to the brain should have a scan performed within 2 months of start of study to rule out brain metastasis (for example breast, lung, melanoma, sarcoma, etc.); - Subjects unable to swallow oral medications or with pre-existing gastrointestinal disorders that might interfere with proper absorption of oral drugs; - Subjects with a history of major surgery within 28 days of first receipt of study drug; - Nursing or pregnant women; - Subjects with any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding that, in the opinion of the Investigator, contraindicates the use of MGCD265 Drug Product or that may render the subject at excessively high risk for treatment complications; or - Subjects with a known hypersensitivity to any of the components of the MGCD265 Drug Product.
  •   Email
  •   Print
  •   Share
  • Make an Appointment

    • For adults:
      877-442-3324 (877-442-DFCI)

    • Quick access:
      Appointments as soon as the next day for new adult patients

    • For children:
      888-733-4662 (888-PEDI-ONC)

    • Make Appointment Online
dana farber logo

450 Brookline Avenue
Boston, MA 02215

Call us toll-free: 866-408-DFCI (3324)

Connect with us

Dana-Farber/Brigham and Women’s Cancer Center is ranked #4 nationally and the best in New England.


Dana-Farber/Boston Children's is ranked the #1 pediatric cancer center.

Sign-up for newsletters